In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
INDICATIONS:Cholangiocarcinoma (in adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement).
Infigratinib can cause retinal pigment epithelial detachment (RPED), which may result in symptoms such as blurred vision. Perform a comprehensive ophthalmic examination including optical coherence tomography prior to initiation of infigratinib, at 1 month, at 3 months, and then every 3 months thereafter during treatment.
Please login to view the rest of this drug profile.